Ivana Stojanović, PhD
Principal Research Fellow
Department of Immunology, Institute for Biological Research “Siniša Stanković”, National Institute of the Republic of Serbia, University of Belgrade
Ivana Stojanović is a Principal research fellow who finished Molecular Biology and Physiology graduate studies at the Faculty of Biology, University of Belgrade in 2001. Dr Stojanovic received her PhD in Immunology from the Faculty of Biology, University of Belgrade in 2004. Since 2001 she has been working in the Department of Immunology, Institute for Biological Research “Siniša Stanković“ – National Institute of the Republic of Serbia (IBISS), University of Belgrade. She participated in three national projects financed by the Ministry of Education, Science and Technological Development of the Republic of Serbia, two projects funded by the Science Fund of the Republic of Serbia, one innovation project and four international projects. Dr. Stojanović was the principal investigator in the project “The role of macrophage migration inhibitory factor in beta cell apoptosis and pathogenesis of obesity-associated type 2 diabetes”, which was funded by the EFSD/AstraZeneca Young Investigator Award (2007-2009), as well as in the project “Generation of insulin-specific T regulatory cells for the treatment of type 1 diabetes”, funded by the Iacocca Family Foundation (USA) (2016-2017), and in the Serbian Science and Diaspora Collaboration Program funded by the Science Fund (2020-2022). Dr. Stojanović supervised 7 Master and 3 PhD theses. She is a lecturer at the PhD programme at the Faculty of Biology, University of Belgrade. Currently, Dr. Stojanović is a leader of the Group for Diabetes Study at Department of Immunology, IBISS that focuses on the basics of the pathogenesis of type 1 diabetes and the possibilities of diabetes modulation through innovative therapeutic approaches. Her work includes the modulation of ILC3 and regulatory T cells by AHR and FFAR2 receptors as well as the application of mesenchymal stem cells and plant-derived compounds for the treatment of type 1 diabetes using a mouse model. Dr. Stojanović has published 76 full-length peer-reviewed articles in international journals and 2 chapters in international books with an h-index 24 and a total number of over 1900 citations (excluding auto-citations).